AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25835233 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 tablets (2000 IU/day) for six months
Number of subjects: 126
Study 22307529 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% gentamicin cream
Number of subjects: 16
Study 22307529 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine jelly
Number of subjects: 16
Study 19542998 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg) during sevoflurane anesthesia
Number of subjects: 80
Study 19542998 — intervention group
Group type: COMPARATOR
Intervention: Normal saline during sevoflurane anesthesia
Number of subjects: 80
Study 19542998 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (0.5 mg/kg) during desflurane anesthesia
Number of subjects: 80
Study 19542998 — intervention group
Group type: COMPARATOR
Intervention: Normal saline during desflurane anesthesia
Number of subjects: 80
Study 17324413 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent retrieval (group B)
Number of subjects: 46
Study 17324413 — intervention group
Group type: COMPARATOR
Intervention: Stents left in place (group A)
Number of subjects: 46
Study 17324413 — intervention group
Group type: COMPARATOR
Intervention: Stents left in place (non-randomized group)
Number of subjects: 46
Study 15149253 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed stress with adaptive tracking algorithm to adjust response deadlines
Number of subjects: 0
Study 15149253 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeded decisions based on several types of information
Number of subjects: 0
Study 11605289 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating tibia component
Number of subjects: 0
Study 11605289 — intervention group
Group type: COMPARATOR
Intervention: Fixed polyethylene inlay
Number of subjects: 0
Study 9801975 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin during orthotopic liver transplantation (OLT)
Number of subjects: 47
Study 9801975 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin during cardiac surgery
Number of subjects: 47
Study 9801975 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal circulation during cardiac surgery
Number of subjects: 47
Study 9801975 — intervention group
Group type: COMPARATOR
Intervention: High-dose aprotinin
Number of subjects: 47
Study 7925538 — intervention group
Group type: EXPERIMENTAL
Intervention: Color flow Doppler sonography (CFDS)
Number of subjects: 21
Study 7925538 — intervention group
Group type: COMPARATOR
Intervention: Voiding cystourethrography (VCU)
Number of subjects: 21
Study 7925538 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after antireflux operations
Number of subjects: 21
Study 2154316 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for nonseminomatous germ cell tumors
Number of subjects: 0
Study 2154316 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging systems for germ cell tumors
Number of subjects: 0
Study 2154316 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic approaches (surgery, chemotherapy, surgery plus chemotherapy)
Number of subjects: 0
Study 2154316 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically relevant staging systems
Number of subjects: 0
Study 842382 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa treatment for 6 months
Number of subjects: 0
Study 842382 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31145386 — intervention group
Group type: EXPERIMENTAL
Intervention: Game Profile-Based Training (GPBT)
Number of subjects: 20
Study 31145386 — intervention group
Group type: COMPARATOR
Intervention: Small-Sided Games (SSG)
Number of subjects: 20
Study 30786861 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week moderate-intensity exercise program (Borg perceived rating scale 13-14), at least three times weekly; one supervised group training and two home-based sessions
Number of subjects: 724
Study 30786861 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 724
Study 28005705 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal treatment applied mainly in the distal branches beyond the main bifurcation (n = 24)
Number of subjects: 51
Study 28005705 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment restricted to the main renal artery (n = 21)
Number of subjects: 51
Study 26423500 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: sectioned and precontoured metal matrix and elastic wedge (G2‐SME)
Number of subjects: 30
Study 26423500 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: metal matrix coupled to a carrier matrix and wood wedge (G1‐MMW)
Number of subjects: 30
Study 26423500 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: polyester strip and reflective wedge (G3‐PMR)
Number of subjects: 30
Study 23237479 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (20 min, 1 mA) to the left dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 46
Study 23237479 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 46
Study 21665047 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-mg modified-release tablet of metoclopramide every 12 hours
Number of subjects: 26
Study 21665047 — intervention group
Group type: COMPARATOR
Intervention: 10-mg immediate-release tablet of metoclopramide every 8 hours
Number of subjects: 26
Study 17941873 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 + met/pio
Number of subjects: 181
Study 17941873 — intervention group
Group type: COMPARATOR
Intervention: met/pio
Number of subjects: 181
Study 16455425 — intervention group
Group type: EXPERIMENTAL
Intervention: Marathon running
Number of subjects: 45
Study 16342231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 43
Study 16342231 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 43
Study 14597948 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 20
Study 14597948 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 20
Study 14597948 — intervention group
Group type: COMPARATOR
Intervention: aspirin plus clopidogrel
Number of subjects: 20
Study 10227336 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol delivered via breath-actuated inhaler (Spiros)
Number of subjects: 60
Study 10227336 — intervention group
Group type: COMPARATOR
Intervention: Albuterol delivered via MDI (Ventolin)
Number of subjects: 60
Study 9156929 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign mastopathy
Number of subjects: 0
Study 9156929 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1914371 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg phenylpropanolamine and 250 mg caffeine
Number of subjects: 6
Study 1914371 — intervention group
Group type: COMPARATOR
Intervention: 25 mg phenylpropanolamine
Number of subjects: 6
Study 1914371 — intervention group
Group type: COMPARATOR
Intervention: 250 mg caffeine
Number of subjects: 6
Study 1914371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7048589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy without drainage
Number of subjects: 100
Study 7048589 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomy with drainage
Number of subjects: 100
Study 29797914 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut implantation at stellate ganglion combined with oral administration of alendronate sodium
Number of subjects: 60
Study 29797914 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of alendronate sodium alone
Number of subjects: 60
Study 28319454 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine
Number of subjects: 332
Study 28319454 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated hepatitis A vaccine
Number of subjects: 332
Study 26151336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingesting 10 g fat
Number of subjects: 16
Study 26151336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingesting 40 g fat
Number of subjects: 16
Study 26151336 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 g fat)
Number of subjects: 16
Study 26151336 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 g fat)
Number of subjects: 16
Study 23964055 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 g high-glucoraphanin (HG) broccoli
Number of subjects: 0
Study 23964055 — intervention group
Group type: COMPARATOR
Intervention: 400 g standard broccoli
Number of subjects: 0
Study 23964055 — intervention group
Group type: COMPARATOR
Intervention: 400 g peas
Number of subjects: 0
Study 19729203 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 6 weeks
Number of subjects: 20
Study 19729203 — intervention group
Group type: COMPARATOR
Intervention: Control group (mentally healthy women)
Number of subjects: 20
Study 18949312 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavor-containing dentifrice
Number of subjects: 50
Study 18949312 — intervention group
Group type: COMPARATOR
Intervention: Non-flavor-containing dentifrice
Number of subjects: 50
Study 16546473 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (ROS) 4 mg daily for 12 weeks
Number of subjects: 21
Study 12775730 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Number of subjects: 463
Study 12775730 — intervention group
Group type: COMPARATOR
Intervention: LV5FU2
Number of subjects: 463
Study 10703675 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d)
Number of subjects: 23
Study 10703675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10703675 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 23
Study 9381523 — intervention group
Group type: EXPERIMENTAL
Intervention: Candoxatrilat (100 mg i.v.)
Number of subjects: 12
Study 8222497 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of contraceptive pill (250 micrograms levonorgestrel and 50 micrograms ethinyl estradiol)
Number of subjects: 819
Study 8222497 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal administration of contraceptive pill (250 micrograms levonorgestrel and 50 micrograms ethinyl estradiol)
Number of subjects: 819
Study 2949683 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% miconazole powder
Number of subjects: 208
Study 2949683 — intervention group
Group type: EXPERIMENTAL
Intervention: Talcum powder with 2% salicylic acid and boric acid
Number of subjects: 208
Study 29961187 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (Cr‐Pic) at 1.2 mg kg‐1
Number of subjects: 120
Study 29961187 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (Cr‐Pic) at 1.8 mg kg‐1
Number of subjects: 120
Study 29961187 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (Cr‐Pic) at 1.2 mg kg‐1 and 1.8 mg kg‐1
Number of subjects: 120
Study 29961187 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate (Cr‐Pic)
Number of subjects: 120
Study 29961187 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet with 1.8 mg kg‐1 Cr
Number of subjects: 120
Study 27346880 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 0.5 mg/day for 6 months
Number of subjects: 18
Study 27346880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 25545924 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking school bus intervention
Number of subjects: 8
Study 25545924 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study 22365897 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 10mg
Number of subjects: 20
Study 22365897 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam 0.5mg
Number of subjects: 20
Study 22365897 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5mg + Oxycodone 10mg
Number of subjects: 20
Study 22365897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20550052 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (17P)
Number of subjects: 193
Study 20550052 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 193
Study 18656072 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisional balance exercise promoting CT and NGC screening
Number of subjects: 192
Study 15906783 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg MR o.d.) for 12 weeks
Number of subjects: 261
Study 12712350 — intervention group
Group type: EXPERIMENTAL
Intervention: Tennis matches (TEC)
Number of subjects: 31
Study 12712350 — intervention group
Group type: COMPARATOR
Intervention: Simulated orienteering (OTC)
Number of subjects: 31
Study 10856736 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone infusion for 48 hours
Number of subjects: 951
Study 10856736 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (placebo infusion for 48 hours)
Number of subjects: 951
Study 8674324 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisofylline (CT1501R)
Number of subjects: 69
Study 8674324 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 69
Study 8674324 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 69
Study 8674324 — intervention group
Group type: COMPARATOR
Intervention: At-risk patients who did not develop ARDS (group A)
Number of subjects: 69
Study 8674324 — intervention group
Group type: EXPERIMENTAL
Intervention: At-risk patients who developed ARDS (group B)
Number of subjects: 69
Study 8674324 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ARDS at the time of admission (group C)
Number of subjects: 69
Study 1909228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 116
Study 1909228 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 116
Study 6347152 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oxymetazoline hydrochloride 0.025%
Number of subjects: 2
Study 30325891 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated quadrivalent influenza vaccine (IIV4)
Number of subjects: 433
Study 30325891 — intervention group
Group type: COMPARATOR
Intervention: Control (no vaccine)
Number of subjects: 433
Study 29136227 — intervention group
Group type: EXPERIMENTAL
Intervention: PGS (Day-3 cleavage-stage)
Number of subjects: 99
Study 29136227 — intervention group
Group type: COMPARATOR
Intervention: Control (no PGS)
Number of subjects: 99
Study 27129842 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (PALO)
Number of subjects: 1114
Study 27129842 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (GRA)
Number of subjects: 1114
Study 23727146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic gas mixture for 30 min
Number of subjects: 12
Study 23727146 — intervention group
Group type: COMPARATOR
Intervention: Room air for 30 min
Number of subjects: 12
Study 23727146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic gas mixture for 60 min
Number of subjects: 12
Study 23727146 — intervention group
Group type: COMPARATOR
Intervention: Room air for 60 min
Number of subjects: 12
Study 23155956 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 100 mg at night and 300 mg orally two hours before surgery
Number of subjects: 61
Study 23155956 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin (control group)
Number of subjects: 61
Study 20479421 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 668
Study 20479421 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 668
Study 20479421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both study arms
Number of subjects: 668
Study 20479421 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of CA
Number of subjects: 668
Study 18833819 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC)
Number of subjects: 0
Study 18833819 — intervention group
Group type: COMPARATOR
Intervention: Conventional cervical testing (CCT)
Number of subjects: 0
Study 16101609 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 150
Study 16101609 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 150
Study 16101609 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 11921115 — intervention group
Group type: EXPERIMENTAL
Intervention: LDEE-CD (levodopa ethylester-carbidopa)
Number of subjects: 62
Study 11921115 — intervention group
Group type: COMPARATOR
Intervention: LD-CD (levodopa-carbidopa)
Number of subjects: 62
Study 10733041 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight children
Number of subjects: 518
Study 10733041 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood body mass index
Number of subjects: 518
Study 10733041 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal blood pressure outside pregnancy
Number of subjects: 518
Study 10733041 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin during pregnancy
Number of subjects: 518
Study 10733041 — intervention group
Group type: COMPARATOR
Intervention: Other maternal characteristics (blood pressure, smoking, weight gain, weight at 20 weeks' gestation, glycemia) and size at birth (birth weight, ponderal index, head circumference/length ratio, small for gestational age)
Number of subjects: 518
Study 8866628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 30
Study 8866628 — intervention group
Group type: COMPARATOR
Intervention: Captopril (CAPT)
Number of subjects: 30
Study 1734386 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (10 days of oral treatment)
Number of subjects: 93
Study 1734386 — intervention group
Group type: COMPARATOR
Intervention: Mupirocin (10 days of topical treatment)
Number of subjects: 93
Study 6093182 — intervention group
Group type: EXPERIMENTAL
Intervention: Desimipramine (DMI) 50 mg IV
Number of subjects: 36
Study 6093182 — intervention group
Group type: EXPERIMENTAL
Intervention: Desimipramine (DMI) 25 mg IV
Number of subjects: 36
Study 6093182 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorimipramine (CI) 25 mg IV
Number of subjects: 36
Study 6093182 — intervention group
Group type: COMPARATOR
Intervention: Sulpiride (100 mg IV)
Number of subjects: 36
Study 6093182 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (10 mg IV)
Number of subjects: 36
Study 31283957 — intervention group
Group type: EXPERIMENTAL
Intervention: Angelica keiskei intake
Number of subjects: 20
Study 29336628 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing 178 mg satiereal, 100 mg naringin, and 2,000 IU vitamin D3 daily (SUPP)
Number of subjects: 20
Study 29336628 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 26603744 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 2348
Study 26603744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2348
Study 26603744 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP addition to models
Number of subjects: 2348
Study 25380092 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative SP CO2 laser
Number of subjects: 20
Study 25380092 — intervention group
Group type: COMPARATOR
Intervention: Ablative fractional CO2 laser
Number of subjects: 20
Study 22185496 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially Evaluated Cold Pressor Test (SECPT)
Number of subjects: 40
Study 22185496 — intervention group
Group type: COMPARATOR
Intervention: Warm water control procedure
Number of subjects: 40
Study 20454497 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg dose)
Number of subjects: 13
Study 20454497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 17507738 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g/d of protein
Number of subjects: 10
Study 17507738 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g/d of protein
Number of subjects: 10
Study 17507738 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 g/d of protein
Number of subjects: 10
Study 17507738 — intervention group
Group type: EXPERIMENTAL
Intervention: All protein intakes (50 g, 100 g, 200 g)
Number of subjects: 10
Study 17507738 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-day modification of protein intake
Number of subjects: 10
Study 16160649 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed FDG PET imaging
Number of subjects: 86
Study 16160649 — intervention group
Group type: COMPARATOR
Intervention: Early FDG PET imaging
Number of subjects: 86
Study 11803082 — intervention group
Group type: EXPERIMENTAL
Intervention: TA‐CD therapeutic vaccine at 13 microg
Number of subjects: 34
Study 11803082 — intervention group
Group type: EXPERIMENTAL
Intervention: TA‐CD therapeutic vaccine at 82 microg
Number of subjects: 34
Study 11803082 — intervention group
Group type: EXPERIMENTAL
Intervention: TA‐CD therapeutic vaccine at 709 microg
Number of subjects: 34
Study 11803082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11803082 — intervention group
Group type: EXPERIMENTAL
Intervention: TA‐CD therapeutic vaccine (all doses combined)
Number of subjects: 34
Study 12176783 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary single-agent epirubicin (120 mg/m(2) every 3 weeks for three cycles)
Number of subjects: 319
Study 12176783 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery and breast irradiation
Number of subjects: 319
Study 9825179 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (120 mg/d) for 28 days
Number of subjects: 144
Study 9825179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 7854512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin
Number of subjects: 0
Study 7854512 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 0
Study 7854512 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective adsorption
Number of subjects: 0
Study 2496977 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide acetate 400 mg
Number of subjects: 38
Study 2496977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 337466 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmic acid treatment
Number of subjects: 99